94. 原発性硬化性胆管炎 Primary sclerosing cholangitis Clinical trials / Disease details
臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03561584 (ClinicalTrials.gov) | July 1, 2018 | 14/5/2018 | Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis | A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | Drug: Sulfasalazine;Drug: Placebo | Brigham and Women's Hospital | NULL | Recruiting | 15 Years | 80 Years | All | 42 | Phase 2 | United States |